Short-term Sugary Beverage Consumption on Glucose Control and Cardiovascular Disease Risk Factors

Not Applicable

Completed

• Conditions: Metabolic Syndrome

• Registration Number: NCT04118257
• Lead Sponsor: Kansas State University

Brief Summary

Our goal is to determine how the addition of sugar-sweetened beverages to the diet affects glucose control, cardiovascular disease risk factors, and pulmonary function in healthy, young adults.

Detailed Description

In a 3-arm randomized controlled trial, 36 participants consumed one of three beverages for three weeks: water (W), caffeine-free soda (S), or 100% fruit juice (FJ). Participants consumed two servings/day (\~710mL) of their randomized beverage for three weeks, along with their habitual diets. At baseline and following the 3-week intervention, participants completed glucose control, cardiovascular disease risk factor, and pulmonary function assessments.

Study Timeline

• Study Start: 2017-02-10
• Primary Completion: 2018-11-14
• Study Completion: 2018-11-14
• Status Verified: 2019-10
• Study First Submitted: 2019-10-01
• Study First Submitted QC: 2019-10-04
• Last Update Submitted: 2019-10-04
• Study First Posted: 2019-10-08
• Last Update Posted: 2019-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Free from diagnosis of diabetes and pulmonary illness
• Have no intake of glucose or lipid lowering medication.

Exclusion Criteria

• Smoke
• Currently pregnant
• Have bronchitis
• Have more than 2 risk factors for cardiovascular disease, as defined by the American College of Sports Medicine (ACSM).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in glucose iAUC	Week 0 and Week 3	Glucose obtained from blood sample in a fasted state and in response to a meal

Secondary Outcome Measures

Name	Time	Method
Change in plasma lipids	Week 0 and Week 3	Total cholesterol (TC), LDL-c , VLDL-c, HDL-c , triglycerides (TG) from blood sample in a fasted state and following consumption of a meal
Change in blood pressure	Week 0 and Week 3	Evaluated via automated sphygmomanometer.
Change in serum fructosamine	Week 0 and Week 3	Fructosamine obtained from blood sample
Change in insulin iAUC	Week 0 and Week 3	Glucose obtained from blood sample in a fasted state and in response to a meal
Change in homeostatic model assessment for insulin resistance	Week 0 and Week 3	Calculated from fasting glucose and insulin values
Change in BMI	Week 0 and Week 3	Weight and height will be combined to report BMI in kg/m\^2
Change in pulmonary function	Week 0 and Week 3	Assessed using the maximum flow-volume loop

Trial Locations

Locations (1)

Lafene Health Center; 🇺🇸 Manhattan, Kansas, United States